Jim Cramer Says Keep an Eye on 'New Pharma' as an Investment Theme

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.
Author:
Publish date:

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly. Cramer says Celgene, which has pulled back recently, could earn $16 a share as soon as 2017. Seattle Genetics could have the largest drug pipeline of any drugmaker that's not part of the big four.

At the time of publication, Cramer was long ___.